31.12.2021 23:44:00
|
iTeos Therapeutics Set to Join S&P SmallCap 600
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5. S&P 500 constituent Centene Corp. (NYSE: CNC) is acquiring Magellan Health in a deal expected to be completed soon pending final conditions.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date | Index Name | Action | Company Name | Ticker | GICS Sector |
January 5, 2022 | S&P SmallCap 600 | Addition | iTeos Therapeutics | ITOS | Health Care |
S&P SmallCap 600 | Deletion | Magellan Health | MGLN | Health Care |
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
FOR MORE INFORMATION:
S&P Dow Jones Indices
index_services@spglobal.com
Media Inquiries
spdji.comms@spglobal.com
View original content:https://www.prnewswire.com/news-releases/iteos-therapeutics-set-to-join-sp-smallcap-600-301452438.html
SOURCE S&P Dow Jones Indices
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Centene Corp.mehr Nachrichten
19.12.24 |
S&P 500-Titel Centene-Aktie: So viel Verlust wäre bei einem Investment in Centene von vor einem Jahr angefallen (finanzen.at) | |
18.12.24 |
Verluste in New York: S&P 500 zum Ende des Mittwochshandels in der Verlustzone (finanzen.at) | |
13.12.24 |
Schwacher Handel in New York: S&P 500 notiert am Freitagnachmittag im Minus (finanzen.at) | |
13.12.24 |
Schwacher Wochentag in New York: S&P 500 verliert mittags (finanzen.at) | |
12.12.24 |
S&P 500-Titel Centene-Aktie: So viel Gewinn hätte ein Investment in Centene von vor 10 Jahren eingebracht (finanzen.at) | |
10.12.24 |
Optimismus in New York: Anleger lassen S&P 500 zum Handelsstart steigen (finanzen.at) | |
05.12.24 |
S&P 500-Wert Centene-Aktie: So viel hätte eine Centene-Investition von vor 5 Jahren eingebracht (finanzen.at) | |
28.11.24 |
S&P 500-Wert Centene-Aktie: So viel Verlust hätte eine Centene-Investition von vor 3 Jahren eingebracht (finanzen.at) |
Analysen zu Centene Corp.mehr Analysen
Aktien in diesem Artikel
Centene Corp. | 57,35 | 0,31% | |
iTeos Therapeutics Inc Registered Shs | 7,42 | 2,77% | |
S&P Global Inc | 469,45 | -0,02% |